6 completed. 6 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
Follow Supranuclear Palsy, Progressive: new trials by email Literature Review of Supranuclear Palsy, Progressive trials Research Report on Supranuclear Palsy, Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg - Dementia-related Psychosis | Phase 3 | Completed | ACADIA Pharmaceuticals Inc. | 392 | 2017-09-27 | 2021-06-21 |
| Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP) | Phase 3 | Completed | Assistance Publique Hopitaux De Marseille | 106 | 2016-07-26 | 2023-07-20 |
| Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Davunetide, Placebo - Progressive Supranuclear Palsy | Phase 2 / Phase 3 | Completed | Allon Therapeutics | 313 | 2010-10-01 | 2013-01-17 |
| Effects of Coenzyme Q10 in PSP and CBD CoQ10 - Progressive Supranuclear Palsy, Neurological Disorders | Phase 2 / Phase 3 | Completed | Lahey Clinic | 2004-01-01 | 2018-06-15 |
Alzheimer Disease (1) · Corticobasal Degeneration (1) · Delusions (1) · Dementia (1) · Dementia, Vascular (1) · Essential Tremor (1) · Hallucinations (1) · Lewy Body Disease (1) · Multiple System Atrophy (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Parkinson Disease (1) · Parkinsonian Disorders (1) · Psychotic Disorders (1)
Basal Ganglia Diseases (6) · Brain Diseases (6) · Central Nervous System Diseases (6) · Cranial Nerve Diseases (6) · Eye Diseases (6) · Movement Disorders (6) · Neurologic Manifestations (6) · Ocular Motility Disorders (6) · Ophthalmoplegia (6) · Paralysis (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Tauopathies (6) · Nervous System Diseases (5) · Neurodegenerative Diseases (5)
Injections (1) · Iodine-123 (1) · Rivastigmine (1) · coenzyme Q10 (1) · davunetide (1) · ioflupane (1) · pimavanserin (1) · sodium phenylbutyrate and taurursodiol (1)
ACADIA Pharmaceuticals Inc. (1) · Allon Therapeutics (1) · Amylyx Pharmaceuticals Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · GE Healthcare (1) · Lahey Clinic (1)
France (4) · United States (4) · Germany (3) · Italy (2) · Spain (2) · United Kingdom (2) · Australia (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Poland (1) · Serbia (1) · Slovakia (1)
Adam Boxer, M.D., PhD. (1) · Diana Apetauerova, MD (1)
PMID 24873720, PMID 28436538, PMID 34289275, PMID 34934801, PMID 38825840, PMID 41286676
2016 (1), 2017 (1)